within Pharmacolibrary.Drugs.ATC.D;

model D07AC04
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0003333333333333333,
    adminDuration  = 600,
    adminMass      = 0.25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D07AC04</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fluocinolone acetonide is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It is primarily used topically for the treatment of skin conditions such as eczema, psoriasis, and dermatitis. The drug is approved for dermatological use and is available in various formulations including creams, ointments, and intravitreal implants for diabetic macular edema.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic parameters have been identified for fluocinolone acetonide in humans in the context of topical or ocular administration. Estimates are provided below based on general corticosteroid pharmacokinetics and product characteristics.</p><h4>References</h4><ol><li><p>Spektor, Z, et al., &amp; Hedrick, J (2022). Pharmacokinetics of ciprofloxacin and fluocinolone acetonide otic solution in pediatric patients. <i>American journal of otolaryngology</i> 43(5) 103573–None. DOI:<a href=&quot;https://doi.org/10.1016/j.amjoto.2022.103573&quot;>10.1016/j.amjoto.2022.103573</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35988360/&quot;>https://pubmed.ncbi.nlm.nih.gov/35988360</a></p></li><li><p>Broggini, M, et al., &amp; Broccali, G (1991). Pharmacokinetics of fluocinolone acetonide in patch versus cream formulations. <i>International journal of clinical pharmacology research</i> 11(1) 17–21. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1874579/&quot;>https://pubmed.ncbi.nlm.nih.gov/1874579</a></p></li><li><p>Gao, HY, &amp; Li Wan Po, A (1994). Topical formulations of fluocinolone acetonide. Are creams, gels and ointments bioequivalent and does dilution affect activity?. <i>European journal of clinical pharmacology</i> 46(1) 71–75. DOI:<a href=&quot;https://doi.org/10.1007/BF00195919&quot;>10.1007/BF00195919</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8005190/&quot;>https://pubmed.ncbi.nlm.nih.gov/8005190</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D07AC04;
